Shares of Illumina, Inc. (NASDAQ:ILMN - Get Free Report) rose 5.7% during trading on Monday . The stock traded as high as $144.47 and last traded at $144.42. Approximately 1,191,095 shares were traded during trading, a decline of 15% from the average daily volume of 1,394,217 shares. The stock had previously closed at $136.69.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on ILMN shares. TD Cowen lifted their price objective on shares of Illumina from $166.00 to $177.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Canaccord Genuity Group upped their price objective on shares of Illumina from $130.00 to $145.00 and gave the company a "hold" rating in a report on Tuesday, November 5th. Morgan Stanley reduced their target price on Illumina from $156.00 to $150.00 and set an "equal weight" rating for the company in a research note on Monday. HSBC raised Illumina from a "hold" rating to a "buy" rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Finally, Citigroup downgraded Illumina from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. Eight investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $165.63.
Check Out Our Latest Stock Report on ILMN
Illumina Trading Up 5.5 %
The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a market capitalization of $22.87 billion, a P/E ratio of -14.48 and a beta of 1.11. The firm has a fifty day moving average price of $140.92 and a 200-day moving average price of $132.88.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.33 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Zacks Investment Management bought a new position in shares of Illumina during the 3rd quarter worth $2,924,000. Freemont Management S.A. bought a new stake in shares of Illumina in the third quarter valued at approximately $1,565,000. Weybosset Research & Management LLC lifted its stake in shares of Illumina by 92.0% during the 3rd quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company's stock valued at $2,354,000 after buying an additional 8,650 shares in the last quarter. B. Riley Wealth Advisors Inc. boosted its holdings in Illumina by 176.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company's stock worth $749,000 after buying an additional 4,579 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in Illumina by 65.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 32,806 shares of the life sciences company's stock valued at $4,278,000 after buying an additional 12,986 shares in the last quarter. 89.42% of the stock is owned by institutional investors.
About Illumina
(
Get Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
